News of Note—Gritstone’s EVP, Trump’s opioid vaccine plan and more

In this week's news of note, Gritstone Oncology hired an industry veteran as its technical operations head. (Pixabay)

Here's some other vaccine news of note for the week.

> Cancer vaccine startup Gritstone Oncology hired Jayant Aphale, Ph.D., as EVP of technical operations. He previously served senior roles at Sarepta, GlaxoSmithKline Vaccines, Acambis and Wyeth Vaccines. Release

> President Donald Trump unveiled a new plan to combat the opioid crisis, including support for research into developing a vaccine for opioid addiction. CNBC article


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

> The Philippine government will seek congressional permission to use refunds for unused Dengvaxia shots from Sanofi to support related medical needs of those already inoculated. ABS-CBN article

> TapImmune’s shares rose 17% premarket Thursday after the company said its TPIV200 T-cell vaccine did well in a phase 1 study in patients with ovarian and breast cancer. MarketWatch article

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.